Boult Wade Tennant
UPC » The UPC in numbers – June 2023 to February 2024

The Unified Patent Court (UPC) has recently released updated details of the case load of the Court* since it commenced operations in June 2023.

In the intervening period the Court of First Instance (CFI) has heard a total of 274 cases, with some key takeaways from the lifespan of the UPC so far being:

Infringement cases: 96 of the cases filed before the CFI have been infringement actions. These have been heard across a variety of local divisions across Europe, but so far the majority have been in Germany (36 in Munich, 20 in Dusseldorf, 11 in Mannheim and five in Hamburg). Paris (nine cases), the Nordic Baltic regional division (five cases),then Milan and the Hague (three case each) and Brussels, Helsinki, Copenhagen and Vienna (one case each) have been less busy.

Counterclaims: Counterclaims for revocation in 39 individual infringement actions have been heard so far.

Types of actions: Infringement actions have to date been by far and away the most common use-case for the Court, with 96 cases. Of the remainder, revocation actions (24 cases) and provisional measures (17 cases) are the next most common forms of actions before the Court.

Language: As was expected, the language of proceedings of the Court has been dominated by German (48% of cases) and English (43% of cases). French (4%), Italian (3%) and Dutch (2%) are marginal use cases so far.

Appeal: The Court of Appeal has started to receive appeals – 27 cases so far.

IPC classes: Class H is the most prevalent class seen before the CFI, with 37 infringement actions, 19 counterclaims and three revocation actions. Class A (20, six and 13 respectively) and Class B (17, seven and three respectively) have seen the next highest usage. Classes D, E, and F have seen far lower uptake, with no counterclaims or revocations, and a total of four infringement actions across all three classes.

*Figures correct up to the end of February 2024

Relevant sectors
Food and beverage
  • Nutrition
  • Retail
  • Beverages
Artificial intelligence and machine learning
Consumer goods and retail
  • Anti-counterfeit devices
  • Moda
  • Health, fitness and sport
  • Beauty
  • Fashion
  • Luxury goods
  • Retail
  • Household goods
Trade marks
  • Mechanical products
  • Services
  • Telecommunications
  • Financial services
  • Cosmetics and perfumery
  • Consumer goods
  • Agrochemicals
  • Catalysts
  • Dispersions and colloids
  • Lubricants
  • Polymers and plastics
  • Advanced materials
  • Composite materials
  • Metallurgy and alloys
  • Nanotechnology
Industrial manufacturing and processing
  • Packaging
  • Polymers and plastics
  • Printing tech
  • Additive manufacturing
  • Coatings
  • Construction
Electronics and electrical devices
  • Restaurants and bars
  • Travel and leisure
  • Testing systems, control systems, signal processing
  • Computer and IT architecture and system design
  • Medical devices
  • Optics
  • Robotics
  • Scientific instruments
  • Semiconductor devices
  • Wearable tech and human interfaces
Communications and networks
  • Oceanography, marine
  • Cloud computing
  • Internet of things (IOT)
  • Wired and wireless networks
Energy and green technologies
  • Solar power
  • Wind turbines
  • Water, oil and gas, nuclear, fusion, fission
  • Clean air
  • Fuel cells and battery technology
  • Renewables and recycling
  • Biofuels
  • Autonomous vehicles
  • Electric vehicles
  • Engines
  • Commercial aviation
  • Defence and security
  • Space and satellites
  • Unmanned aerial vehicles
  • Pharmaceuticalsceutical formulations
  • Diagnostics
  • Drug delivery
  • Generic market entry
  • Medicinal chemistry
  • Methods of production and synthesis
  • Personalised medicine/disease biomarkers
  • Pharmaceutical formulations
  • Polymorphs
  • Small molecule pharmaceuticals
  • Supplementary protection certificates (SPCs)
  • Bioinformatics
  • Next generation sequencing
  • Women’s health products
  • Vaccinology (e.g. viral vectors; mRNA vaccines)
  • Therapeutic antibodies
  • Synthetic biology
  • Stem cell therapies
  • Recombinant protein production and purification
  • Personalised medicine/disease biomarkers
  • Nucleic acid synthesis
  • Supplementary protection certificates (SPCs)
  • Immuno-oncology (e.g. checkpoint inhibitors; modified T cells)
  • GM crops
  • Genomic and molecular tools and methods
  • Gene editing (e.g. CRISPR)
  • Drug delivery
  • Biosimilars
  • Antibody manufacture and formulation
  • Antibody engineering
Medical devices and diagnostics 
  • Immuno-oncology
  • Artificial intelligence
  • Devices
  • Diagnostic instruments
  • Digital health
  • Drug delivery
  • In vitro diagnostics
  • Medtech
Computing and software
  • Digital assistants, virtual assistants and software agents
  • Multimedia, audio/video processing and animation
  • Metaverse, virtual reality (VR) and augmented reality (AR)
  • Data management and storage, databases and data compression
  • Data and software security, cryptography and digital rights management (DRM)
  • Software applications and systems, mobile applications, user interfaces
  • Natural language processing
  • Search engines
  • Robotic process automation
  • Quantum computing
  • Motor capture
  • Machine vision
  • Fintech and adtech
  • Computer games
  • Communications and networks
  • Blockchain and distributed ledgers
  • Bioinformatics
  • Signal processing
  • Artificial intelligence and machine learning